During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
News|Articles|December 1, 2008
Formulary Digital Edition December 2008
Clinical news updates from the 2008 American Heart Association Scientific Sessions; Preferential formulary listing of a proton-pump inhibitor; Drug Watch: Agents in late-stage development for the treatment of multiple sclerosis
Advertisement
Advertisement
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Pope Leo XIV's lung cancer diagnosis puts a spotlight on low U.S. screening rates
2
Chronic hand eczema needs more than topical steroids | Fall Clinical Derm 2026
3
U.S. employer-covered healthcare costs: It’s still the prices
4
Choosing a first biologic for HS, as recommended by Jennifer Hsiao, M.D. | Fall Clinical Derm 2026
5